Zacks.com on MSN15h
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Medindia21h
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US MANAMA, Kingdom of Bahrain, Feb ...
Crispr Therapeutics price target lowered to $82 from $89 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...